Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New registry to monitor growth hormone treatment in kids with rare genetic condition

NCT ID NCT05308927

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 20 times

Summary

This study is a registry that will follow about 221 children with Noonan Syndrome who are already taking or starting Norditropin® for short stature. Researchers will collect information on how the children grow over time, any side effects, and their quality of life. The goal is to better understand the long-term effects and safety of this treatment in real-world settings.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NOONAN SYNDROME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Ap-Hp-Hopital de Bicetre-2

    Le Kremlin-Bicêtre, 94275, France

  • Centre Hospitalier Universitaire D'Angers-2

    Angers, 49033, France

  • Hopital Des Enfants-2

    Toulouse, 31059, France

Conditions

Explore the condition pages connected to this study.